Healthcare Industry News: obstructive sleep apnea
News Release - April 9, 2009
Ventus Medical Appoints John McCutcheon as President and CEOAlso Announces the expansion of PROVENT(R) Sleep Apnea Therapy in Limited US Markets
BELMONT, Calif., April 9 -- (Healthcare Sales & Marketing Network) -- Ventus Medical, Inc. a privately-held, medical device company, focused on transforming the Sleep Disordered Breathing market, today announced the appointment of John McCutcheon as President and Chief Executive Officer, effective April 20, 2009. The company also announced that current CEO Jeffrey Nugent will become Executive Chairman.
Mr. McCutcheon joins Ventus Medical from Emphasys Medical where he was President and CEO for the past seven years. Previously, he was head of Sales and Marketing at Perclose, an Abbott Laboratories company and in senior marketing positions at Devices for Vascular Intervention and Baxter Healthcare.
"John is the ideal leader to drive the commercialization of PROVENT Therapy as a novel treatment of obstructive sleep apnea (OSA). He is a proven leader in the medical device field with nearly 25 years of experience," said Mr. Nugent. "Clinical studies have shown that PROVENT Therapy has the potential to improve the quality of life for millions of people around the world who suffer from this disorder," he added. "We are encouraged by the acceptance we are experiencing at both the physician and patient level at the sleep centers where PROVENT Therapy is currently available."
PROVENT Therapy has been cleared by the Food and Drug Administration and is indicated for the treatment of obstructive sleep apnea. PROVENT Therapy is a daily use, prescription device and works across mild, moderate, and severe OSA.
"I am pleased to join Ventus Medical at this exciting time in the Company's development," said John McCutcheon. "PROVENT Therapy is one of the most innovative products to be introduced into the sleep apnea market in years: it is a convenient, discreet and portable solution. We look forward to working closely with the medical community to meet the need for more patient-friendly, effective sleep apnea treatments."
PROVENT Therapy is currently available in a limited number of markets and is in the process of expanding with the assistance and support of professional sleep physicians in the United States.
Also, Ventus Medical has just been awarded the 2009 Medical Design Excellence Award which recognizes those companies responsible for the ground breaking innovations that are changing the face of healthcare.
Ventus Medical's investors include De Novo Ventures, Mohr Davidow Ventures and the Johnson & Johnson Development Corporation. Information on Ventus Medical and PROVENT Therapy can be found on www.ventusmedical.com and www.proventtherapy.com.
Source: Ventus Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.